fidasimtamab (IBI315) / Hanmi, Innovent Biologics 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fidasimtamab (IBI315) / Hanmi, Innovent Biologics
NCT05608785: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Not yet recruiting
1/2
45
NA
IBI315, Oxaliplatin, Capecitabine, TST001, TQB2450, Anrotinib
Henan Cancer Hospital
Gastric Cancer, Gastroesophageal-junction Cancer
12/23
10/24
NCT04162327: A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Completed
1a/1b
55
RoW
IBI315
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumor
01/22
06/23

Download Options